Skip to Content
Merck

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.

Science (New York, N.Y.) (2020-02-23)
Daniel Wrapp, Nianshuang Wang, Kizzmekia S Corbett, Jory A Goldsmith, Ching-Lin Hsieh, Olubukola Abiona, Barney S Graham, Jason S McLellan
ABSTRACT

The outbreak of a novel coronavirus (2019-nCoV) represents a pandemic threat that has been declared a public health emergency of international concern. The CoV spike (S) glycoprotein is a key target for vaccines, therapeutic antibodies, and diagnostics. To facilitate medical countermeasure development, we determined a 3.5-angstrom-resolution cryo-electron microscopy structure of the 2019-nCoV S trimer in the prefusion conformation. The predominant state of the trimer has one of the three receptor-binding domains (RBDs) rotated up in a receptor-accessible conformation. We also provide biophysical and structural evidence that the 2019-nCoV S protein binds angiotensin-converting enzyme 2 (ACE2) with higher affinity than does severe acute respiratory syndrome (SARS)-CoV S. Additionally, we tested several published SARS-CoV RBD-specific monoclonal antibodies and found that they do not have appreciable binding to 2019-nCoV S, suggesting that antibody cross-reactivity may be limited between the two RBDs. The structure of 2019-nCoV S should enable the rapid development and evaluation of medical countermeasures to address the ongoing public health crisis.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
SARS-COV-2-Spike-RBD epitope (450-469), 95% (HPLC), lyophilized powder
Sigma-Aldrich
SARS-COV-2-Spike-RBD epitope (480-499), ≥95% (HPLC), lyophilized powder
Sigma-Aldrich
Anti-SARS-COV-2-Spike-RBD region Peroxidase conjugated antibody produced in rabbit
Sigma-Aldrich
SARS-COV-2-Spike-RBD epitope (370-394), ≥95% (HPLC), lyophilized powder